Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/82 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME16334941
PMID: | 16334941
LR: | 20061115
CED: | 20051209
DCO: | 20060124
Autoren: | Neil KM; Orth MW; Coussens PM; Chan PS; Caron JP
Titel: | Effects of glucosamine and chondroitin sulfate on mediators of osteoarthritis in cultured equine chondrocytes stimulated by use of recombinant equine interleukin-1beta.
Quelle: | American journal of veterinary research; VOL: 66 (11); p. 1861-9 /200511/
PM: | Print
SU: | IM
Sprache: | English
CY: | United States
JID: | 0375011
ISSN: | 0002-9645
CO: | AJVRAH
Institution: | Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing 48824, USA.
DT: | Journal Article; Research Support, Non-U.S. Gov't
Schlagwörter
CT: | ADAM PROTEINS/biosynthesis; ADAM PROTEINS/genetics; ANIMALS; CARTILAGE, ARTICULAR/cytology; CARTILAGE, ARTICULAR/*drug effects; CARTILAGE, ARTICULAR/enzymology; CARTILAGE, ARTICULAR/metabolism; CHONDROCYTES/drug effects; CHONDROCYTES/enzymology; CHONDROCYTES/metabolism; CHONDROITIN SULFATES/*pharmacology; CYCLOOXYGENASE 2/biosynthesis; CYCLOOXYGENASE 2/genetics; GENE EXPRESSION/drug effects; GLUCOSAMINE/*pharmacology; HORSE DISEASES/*drug therapy; HORSES; INTERLEUKIN-1/*pharmacology; MAP KINASE KINASE 4/biosynthesis; MAP KINASE KINASE 4/genetics; MATRIX METALLOPROTEINASES/biosynthesis; MATRIX METALLOPROTEINASES/genetics; NF-KAPPA B/biosynthesis; NF-KAPPA B/genetics; NITRIC OXIDE SYNTHASE TYPE II/biosynthesis; NITRIC OXIDE SYNTHASE TYPE II/genetics; OSTEOARTHRITIS/drug therapy; OSTEOARTHRITIS/genetics; OSTEOARTHRITIS/metabolism; OSTEOARTHRITIS/*veterinary; PROCOLLAGEN N-ENDOPEPTIDASE/biosynthesis; PROCOLLAGEN N-ENDOPEPTIDASE/genetics; RECOMBINANT PROTEINS/pharmacology; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION/veterinary
CTG: | ADAM-PROTEINE/Biosynthese; ADAM-PROTEINE/Genetik; TIER; KNORPEL, GELENK-/Zytologie; KNORPEL, GELENK-/*Arzneimittelwirkungen; KNORPEL, GELENK-/Enzymologie; KNORPEL, GELENK-/Stoffwechsel; CHONDROZYTEN/Arzneimittelwirkungen; CHONDROZYTEN/Enzymologie; CHONDROZYTEN/Stoffwechsel; CHONDROITINSULFATE/*Pharmakologie; CYCLOOXYGENASE 2/Biosynthese; CYCLOOXYGENASE 2/Genetik; GENEXPRESSION/Arzneimittelwirkungen; GLUCOSAMIN/*Pharmakologie; PFERDEKRANKHEITEN/*Arzneimitteltherapie; PFERDE; INTERLEUKIN-1/*Pharmakologie; MAP-KINASE-KINASE 4/Biosynthese; MAP-KINASE-KINASE 4/Genetik; MATRIX-METALLOPROTEINASEN/Biosynthese; MATRIX-METALLOPROTEINASEN/Genetik; NF-KAPPA B/Biosynthese; NF-KAPPA B/Genetik; STICKSTOFFMONOXID-SYNTHASE TYP II/Biosynthese; STICKSTOFFMONOXID-SYNTHASE TYP II/Genetik; OSTEOARTHROSE/Arzneimitteltherapie; OSTEOARTHROSE/Genetik; OSTEOARTHROSE/Stoffwechsel; OSTEOARTHROSE/*Veterinärmedizin; PROCOLLAGEN-N-ENDOPEPTIDASE/Biosynthese; PROCOLLAGEN-N-ENDOPEPTIDASE/Genetik; REKOMBINANTE PROTEINE/Pharmakologie; REVERSE TRANSKRIPTASE-POLYMERASE-KETTENREAKTION/Veterinärmedizin
TE: | Interleukin-1; NF-kappa B; Recombinant Proteins; Glucosamine/3416-24-8; Chondroitin Sulfates/9007-28-7; Nitric Oxide Synthase Type II/E.C. 1.14.13.39; Cyclooxygenase 2/E.C. 1.14.99.1; MAP Kinase Kinase 4/E.C. 2.7.1.-; ADAM Proteins/E.C. 3.4.24.-; Matrix Metalloproteinases/E.C. 3.4.24.-; aggrecanase-1/E.C. 3.4.24.-; Procollagen N-Endopeptidase/E.C. 3.4.24.14
CR: | 3416-24-8; 9007-28-7; E.C. 1.14.13.39; E.C. 1.14.99.1; E.C. 2.7.1.-; E.C. 3.4.24.-; E.C. 3.4.24.-; E.C. 3.4.24.-; E.C. 3.4.24.14
AB: | OBJECTIVE: To determine whether glucosamine and chondroitin sulfate (CS) at concentrations approximating those achieved in plasma by oral administration would influence gene expression of selected mediators of osteoarthritis in cytokine-stimulated equine articular chondrocytes. SAMPLE POPULATION: Samples of grossly normal articular cartilage obtained from the metacarpophalangeal joint of 13 horses. PROCEDURE: Equine chondrocytes in pellet culture were stimulated with a subsaturating dose of recombinant equine interleukin (reIL)-1beta. Effects of prior incubation with glucosamine (2.5 to 10.0 microg/mL) and CS (5.0 to 50.0 microg/mL) on gene expression of matrix metalloproteinase (MMP)-1, -2, -3, -9, and -13; aggrecanase 1 and 2; inducible nitric oxide synthase (iNOS); cyclooxygenase (COX)-2; nuclear factor kappaB; and c-Jun-N-terminal kinase (JNK) were assessed by use of a quantitative real-time polymerase chain reaction assay. RESULTS: Glucosamine at a concentration of 10 microg/mL significantly reduced reIL-1beta-induced mRNA expression of MMP-13, aggrecanase 1, and JNK. Reductions in cytokine-induced expression were also observed for iNOS and COX-2. Chondroitin sulfate had no effect on gene expression at the concentrations tested. CONCLUSIONS AND CLINICAL RELEVANCE: Concentrations of glucosamine similar to those achieved in plasma after oral administration in horses exerted pretranslational regulation of some mediators of osteoarthritis, an effect that may contribute to the cartilage-sparing properties of this aminomonosaccharide. Analysis of results of this study indicated that the influence of CS on pretranslational regulation of these selected genes is limited or lacking.

» Volltext »
» Fenster schließen »